-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Contrasting Abliva AB (Publ) (OTCMKTS:NEVPF) and Seelos Therapeutics (NASDAQ:SEEL)
Contrasting Abliva AB (Publ) (OTCMKTS:NEVPF) and Seelos Therapeutics (NASDAQ:SEEL)
Abliva AB (publ) (OTCMKTS:NEVPF – Get Rating) and Seelos Therapeutics (NASDAQ:SEEL – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.
Insider and Institutional Ownership
29.6% of Seelos Therapeutics shares are held by institutional investors. 5.1% of Seelos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Get Abliva AB (publ) alerts:Profitability
This table compares Abliva AB (publ) and Seelos Therapeutics' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Abliva AB (publ) | N/A | -159.15% | -120.99% |
Seelos Therapeutics | N/A | -239.70% | -132.82% |
Analyst Ratings
This is a breakdown of recent ratings and target prices for Abliva AB (publ) and Seelos Therapeutics, as provided by MarketBeat.com.Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Abliva AB (publ) | 0 | 0 | 0 | 0 | N/A |
Seelos Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
Seelos Therapeutics has a consensus price target of $4.00, indicating a potential upside of 419.35%. Given Seelos Therapeutics' higher probable upside, analysts plainly believe Seelos Therapeutics is more favorable than Abliva AB (publ).
Valuation and Earnings
This table compares Abliva AB (publ) and Seelos Therapeutics' top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Abliva AB (publ) | $20,000.00 | 201.51 | -$14.40 million | ($0.04) | -0.25 |
Seelos Therapeutics | $380,000.00 | 217.21 | -$66.05 million | ($0.79) | -0.97 |
Abliva AB (publ) has higher earnings, but lower revenue than Seelos Therapeutics. Seelos Therapeutics is trading at a lower price-to-earnings ratio than Abliva AB (publ), indicating that it is currently the more affordable of the two stocks.
Summary
Seelos Therapeutics beats Abliva AB (publ) on 6 of the 11 factors compared between the two stocks.
About Abliva AB (publ)
(Get Rating)
Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
About Seelos Therapeutics
(Get Rating)
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.
Receive News & Ratings for Abliva AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abliva AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.
Abliva AB (publ) (OTCMKTS:NEVPF – Get Rating) and Seelos Therapeutics (NASDAQ:SEEL – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.
Abliva AB(Publ)(OTCMKTS:NEVPF-GET Rating)和Seelos Treateutics(納斯達克:SEEL-GET Rating)都是小盤醫療公司,但哪種投資更具優勢?我們將根據這兩家公司的機構所有權、分析師建議、收益、估值、風險、盈利能力和股息的實力進行比較。
Insider and Institutional Ownership
內部人與機構持股
29.6% of Seelos Therapeutics shares are held by institutional investors. 5.1% of Seelos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Seelos治療公司29.6%的股份由機構投資者持有。Seelos Treateutics 5.1%的股份由內部人士持有。強大的機構持股表明,大型基金管理公司、對衝基金和捐贈基金相信,一隻股票的長期表現將好於大盤。
Profitability
盈利能力
This table compares Abliva AB (publ) and Seelos Therapeutics' net margins, return on equity and return on assets.
下表比較了Abliva AB(Publ)和Seelos Treeutics的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
Abliva AB (publ) | N/A | -159.15% | -120.99% |
Seelos Therapeutics | N/A | -239.70% | -132.82% |
淨利潤率 | 股本回報率 | 資產回報率 | |
Abliva AB(酒吧) | 不適用 | -159.15% | -120.99% |
Seelos治療公司 | 不適用 | -239.70% | -132.82% |
Analyst Ratings
分析師評級
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Abliva AB (publ) | 0 | 0 | 0 | 0 | N/A |
Seelos Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
Abliva AB(酒吧) | 0 | 0 | 0 | 0 | 不適用 |
Seelos治療公司 | 0 | 0 | 2 | 0 | 3.00 |
Seelos Therapeutics has a consensus price target of $4.00, indicating a potential upside of 419.35%. Given Seelos Therapeutics' higher probable upside, analysts plainly believe Seelos Therapeutics is more favorable than Abliva AB (publ).
Seelos治療公司的共識目標價為4.00美元,表明潛在漲幅為419.35。考慮到Seelos治療公司更有可能上行,分析師們顯然認為Seelos治療公司比Abliva AB(Publ)更有利。
Valuation and Earnings
估值和收益
This table compares Abliva AB (publ) and Seelos Therapeutics' top-line revenue, earnings per share (EPS) and valuation.
此表比較了Abliva AB(Publ)和Seelos Treeutics的營收、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Abliva AB (publ) | $20,000.00 | 201.51 | -$14.40 million | ($0.04) | -0.25 |
Seelos Therapeutics | $380,000.00 | 217.21 | -$66.05 million | ($0.79) | -0.97 |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
Abliva AB(酒吧) | $20,000.00 | 201.51 | -1,440萬美元 | ($0.04) | -0.25 |
Seelos治療公司 | $380,000.00 | 217.21 | -6,605萬元 | ($0.79) | -0.97 |
Abliva AB (publ) has higher earnings, but lower revenue than Seelos Therapeutics. Seelos Therapeutics is trading at a lower price-to-earnings ratio than Abliva AB (publ), indicating that it is currently the more affordable of the two stocks.
Abliva AB(Publ)比Seelos Treeutics有更高的收益,但收入更低。Seelos治療公司的市盈率低於Abliva AB(Publ),這表明它目前是兩隻股票中更負擔得起的一隻。
Summary
摘要
Seelos Therapeutics beats Abliva AB (publ) on 6 of the 11 factors compared between the two stocks.
Seelos Treeutics在兩隻股票之間比較的11個因素中有6個超過了Abliva AB(Publ)。
About Abliva AB (publ)
關於Abliva AB(Publ)
(Get Rating)
(獲取評級)
Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Abliva AB(Publ)開發治療原發線粒體疾病的藥物。該公司正在開發KL1333,它處於慢性治療初級線粒體疾病的2/3階段臨牀試驗;NV354,正在準備治療複雜I缺乏的初級線粒體疾病的臨牀試驗;以及NeuroSTAT,處於創傷性腦損傷的1b/2a階段臨牀研究。它與異構酶、永進製藥、賓夕法尼亞大學、費城兒童醫院和奧羅博羅斯儀器公司達成了合作協議。該公司前身為NeuroVive Pharmtics AB(Publ),並於2020年5月更名為Abliva AB(Publ)。Abliva AB(Publ)成立於2000年,總部設在瑞典隆德。
About Seelos Therapeutics
關於Seelos Treateutics
(Get Rating)
(獲取評級)
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.
Seelos治療公司是一家臨牀階段的生物製藥公司,專注於治療中樞神經系統、呼吸系統和其他疾病的治療藥物的開發和商業化。該公司的主要項目是SLS-002,一種用於治療嚴重抑鬱障礙患者急性自殺意念和行為的鼻腔外消旋氯胺酮;SLS-005,一種用於治療肌萎縮側索硬化症和Sanfilippo綜合徵的蛋白質穩定劑;以及SLS-006,一種用於治療帕金森氏病(PD)患者的部分多巴胺激動劑。其臨牀前計劃包括用於治療帕金森病患者的抗α-突觸核蛋白多肽抑制劑SLS-007;用於治療哮喘慢性炎症和兒童孤兒適應症的口服趨化受體同源分子拮抗劑SLS-008;用於治療帕金森病的SLS-004;用於治療發作性睡病和相關疾病的組胺H3A受體拮抗劑SLS-010;以及用於術後疼痛管理的注射療法SLS-012。Seelos治療公司成立於1987年,總部設在紐約。
Receive News & Ratings for Abliva AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abliva AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.
接受Abliva AB(Publ)日報的新聞和評級-在下面輸入您的電子郵件地址,以通過MarketBeat.com的免費每日電子郵件時事通訊接收對Abliva AB(Publ)和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧